Table 3.
Absolute Risk (AR), AR Reduction (ARR), Crude and Adjusted Odds Ratios (OR) with Bonferroni adjusted confidence interval, and p values for Hospitalization due to Worsening Heart Failure in Women with Heart Failure Receiving Digoxin by Serum Digoxin Concentration (SDC) Versus Placebo (Reference), Data for All Women, and Stratified by Ejection Fraction (EF) 35%
| N (%) | AR | ARR | Crude OR (97.5% CI) | P value | Adjusted* OR (97.5% CI)** | P value | ||
|---|---|---|---|---|---|---|---|---|
| All Women (N=1,366) | Placebo | 955 (69.9%) | 32.8% | Reference | 1 | Reference | 1 | Reference |
| SDC 0.5-1.1 ng/ml | 282 (20.6%) | 25.5% | 7.3% | 0.70 (0.50 – 0.99) | 0.021 | 0.75 (0.52 – 1.07) | 0.072 | |
| SDC ≥1.2 ng/ml | 129 (9.4%) | 38.0% | -5.2% | 1.26 (0.81 – 1.94) | 0.240 | 1.06 (0.67 – 1.69) | 0.772 | |
| Women with EF <35% (N=677) | Placebo | 463 (68.4%) | 40.4% | Reference | 1 | Reference | 1 | Reference |
| SDC 0.5-1.1 ng/ml | 148 (21.9%) | 29.7% | 10.7% | 0.62 (0.40 – 0.99) | 0.021 | 0.63 (0.39 – 1.00) | 0.026 | |
| SDC ≥1.2 ng/ml | 66 (9.7%) | 45.5% | -5.1% | 1.23 (0.68 – 2.23) | 0.434 | 1.09 (0.59 – 2.03) | 0.747 | |
| Women with EF ≥35% (N=689) | Placebo | 492 (71.4%) | 25.6% | Reference | 1 | Reference | 1 | Reference |
| SDC 0.5-1.1 ng/ml | 134 (19.4%) | 20.9% | 4.7 | 0.77 (0.45 – 1.30) | 0.262 | 0.95 (0.54 – 1.66) | 0.826 | |
| SDC ≥1.2 ng/ml | 63 (9.1%) | 30.2% | -4.6 | 1.25 (0.65 – 2.42) | 0.440 | 1.13 (0.58 – 2.28) | 0.706 |
*
Adjusted for same covariates as in Table 2.
**
Alpha=0.025 (0.05/2) was used to construct individual confidence intervals to achieve an overall 95% confidence intervals using Bonferroni adjustment